ArticleFrontiers in immunology2026
Elucidating the molecular mechanisms of Daifu decoction in ulcerative colitis treatment through a multi-omics framework and experimental verification.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a significant and challenging condition in the digestive system, necessitating the development of effective therapeutic interventions. The Daifu decoction (DFD) is derived from the Lizhong decoction, a classic traditional Chinese Medicine (TCM) formula used to treat digestive diseases. Previous studies have found that DFD has a clear therapeutic effect on UC. This study aimed to investigate the underlying mechanisms of DFD in UC treatment. Methods: A mouse model of dextran sulfate sodium (DSS)-induced UC was established, and mice were treated with DFD using the concentrations 1.6 g/(kg·d), 3.2 g/(kg·d), and 6.4 g/(kg·d) for 7 days. H&E and AB-PAS staining, ELISA, qPCR, and immunofluorescence were selected to assess the role of DFD in alleviating colitis and improving intestinal barrier damage. In addition, untargeted metabolomics and transcriptomics helped investigate the potential mechanism of DFD against UC, 16S rRNA sequencing evaluated the characteristics of the gut microbiota. The key target and downstream molecules were verified by molecular docking, molecular dynamics simulation, qPCR, western blotting, and immunohistochemistry. Results: DFD prevented goblet cell loss, downregulated proinflammatory factors in serum, and improved tight junction mRNA and protein expression in colon tissue. Furthermore, DFD decreased the proportion of pathogenic microbes, while increasing the microbiota diversity and the proportion of beneficial bacterial. The integrated multi-omics analysis revealed that PRKCG was the key target of DFD to improve UC. Molecular docking and molecular dynamics simulations further confirmed that the active components of DFD could bind to PRKCG stably. The results of qPCR, western blotting, and immunohistochemistry revealed that DFD could regulate PKCγ/ERK/NF-κB pathway. Conclusion: DFD can exert therapeutic effects on UC by regulating the PKCγ/ERK/NF-κB signaling pathway and the gut microbiota to restore the intestinal barrier and decrease the secretion of proinflammatory cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.